ArriVent BioPharma Advances Lung Cancer Program, ADC Pipeline
NEWTOWN SQUARE, PA — ArriVent BioPharma (Nasdaq: AVBP) reported first-quarter results as the company advanced late-stage testing of its lung cancer therapy firmonertinib and moved two antibody-drug conjugate programs closer …
ArriVent BioPharma Advances Lung Cancer Program, ADC Pipeline Read More